IC
SNDX icon

Inscription Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Inscription Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,500
Closed -$352K – 369
2021
Q2 		$352K Buy
+20,500
New +$375K 0.04% 231

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Inscription Capital's SNDX Position: Q3 2021 in Review

Inscription Capital sold out of Syndax Pharmaceuticals (SNDX) in Q3 2021, closing a stake of 20,500 shares — an estimated $352K sold.

Inscription Capital first reported a position in SNDX in Q2 2021 and held it in 1 quarter. The position peaked at $352K in Q2 2021. 123 funds tracked by Wall St. Rank hold SNDX as of Q3 2021.

  • Inscription Capital reported no remaining Syndax Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Inscription Capital sold 20,500 Syndax Pharmaceuticals shares in Q3 2021, an estimated $352K.
  • Inscription Capital first reported a position in Syndax Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Inscription Capital's Syndax Pharmaceuticals position peaked at $352K in Q2 2021.
  • 123 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2021.

Based on Inscription Capital's 13F filing for Q3 2021, filed 9 Nov 2021.